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Collaboration is vital
EDITOR—The issue of pharmacists provid-
ing emergency contraception is controver-
sial, äs shown by the contribution by
Stammers, and I am still uncertain about it.1
Although the recent reclassification of
emergency contraception can only broaden
access to this useful product, I would have
reservations about selling this item myself,
not for any issue of conscience (which is
causing great debate in the pharmacy litera-
ture in the United Kingdom) but because
most British Community pharmacies do not
have the facilities to take a history in private.
If pharmacists are going to provide this
service then, äs Stammers suggests, diey
should also be providing information about
local sexual health Services and advocating
their use.
Contact your local sexual health centre
and discuss this issue with them, and you will
find that they are only too willing to help
with the provision of relevant materials. This
issue has the possibility to develop into yet
another of those "them and us" scenarios
between the medical and pharmacy profes-
sions. The time has come for everyone to
work towards a common goal rather than
everyone working in isolation.
Gary Ward dupensary manager,Auckland Hospital
3 Condor Place, Unsworth Heights, Auckland 1030,
New Zealand
garyw@ahsl.co nz
l Stammers T Emergency contraception from pharmacists
misses opportumty BMJ2001,322 1245 (19 May)
Family history and risk of
venous thromboembolism with
oral contraception
Family history is important tool
EDITOR—Cosmi et al in their article claim
that family history has poor diagnostic test
qualities to detect prothrombotic muta-
tions.' They also indicate that overall
population screening is not cost eifective.
Although it always was obvious that family
history would never make a perfect test (of
families with many cases of venous throm-
bosis, up to 40 or 50% have factor V
Leiden2), the finding of an equal predictive
value for a positive and a negative family
history by Cosmi et al is surprising and
might be due to the small numbers included
or the type of history that was considered
"positive."
Even if family history is far frorn perfect
äs a diagnostic test for one or two mutations,
the question is whether one should refrain
frorn using it In our original publication, we
tried to emphasise the meaning of family
history for the prescription of oral contra-
ceptives, and not really äs a clue for the
detection of mutations.* Apart from any
prothrombotic mutation, a strongly positive
family history might point to a tendency for
venous thrombosis that might be taken into
account clinically in the decision whether or
not to use oral contraceptives.
Moreover, even the meaning of a
mutation is diiferent in the context of a posi-
tive family history: the age at first venous
thrombosis with factor V Leiden is about 10
years younger in persons with a positive
family history than in consecutive patients.*
The most important information that one
would like to obtain from a family history is
not a proxy test for factor V Leiden or any
other mutation, but the likelihood that a
woman will develop thrombosis if she uses
oral contraceptives. Whether or not family
history would be valuable for that purpose is
the ultimate test
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Author's reply
EDITOR—The finding of an equal predictive
value of a positive and' negative family
history of venous thromboembolism might
be berause of the type of family history that
was considered to be positive—that is, one
first or second degree relative. However,
because of the demographic changes in Italy
over the past three decades, modern families
are now small and many siblings are
extremely rare. As a result, it would be quite
düBcult to find young women with two or
more relatives with a history of venous
thromboembolism.
Our study was prompted by the ques-
tion whether clinicians can identify women
at risk of venous thromboembolism during
contraception only on the basis of family
history. A positive personal or family history,
or both, can be considered in itself a
contraindication to oral contraception
regardless of any thrombophilic defecL In
the case of a positive history, screening for
thrombophilia may be irrelevant because,
even if no thrombophilic defects are found,
the decision may be based only on clinical
grounds. The problem can arise when clini-
cians obtain a negative personal or family
history. We agree that family history cannot
be a proxy test for any thrombophilic muta-
tion, but it indicates the likelihood that a
woman will develop thrombosis during oral
confraception. ' s
We also know that oral contraceptives
may trigger thromboembolic complications
in women with unrecognised thrombophilic
defects. Thus women with thrombophilic
defects can be considered at higher risk of
developing thrombotic complications, even
though the absolute risk is low. Is it
necessary to search for thrombophilic
defects if personal or family history is nega-
tive? Possibly not if the problem is
considered from an epidemiological point
of view because universal screening is not
cost effective. However, women cannot be
denied the knowledge and the information
about the possibility of screening. We do not
yet have an understanding of the biological
basis of thrombotic complications during
oral contraception and we have no other
means of identifying women at risk of such
complications. Apart from the risk of fatal
pulmonary embolism, the morbidity and
cost and side effects of venous thromboem-
bolism cannot be ignored by clinicians.
Moreover, clinicians constantly face
litigation, which could arise from incom-
plete information and the finding of a
thrombophilic defect after an episode of
venous thromboembolism during orafij
contraception. \
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Author's reply to criücisrn of
study on benzodia/epincs and
risk of hip fracturc
EDITOR—Sgadari et al's ICIUT' coirimented'
on the study that I and soveral oilicis rarried
out to see whether bcu/odia/cpiiius are
associated with an increasod risk ofhip frac- ,
ture.2 We found that they are not.
In their lärge case-conirol Mudy of 9752
patients with hip fractures compared with
38 564 controls, Sgadari et al also found no ;
association between the use of benzodi-
azepines and hip fracture.5 But like us,
though in differertt subgroups, they did find
an association between certain drugs and
hip fracture. They looked at the metabolic
pathways involved, and it seems that in a
specific subgroup of the most elderty
patients these drugs may confer more risk. If
this is not the result of multiple post-hoc
testing it is an interesting finding, and one
we dir! not look at. '
\Vo M.ucd ihat ilu- rosuli.s we found for
individual drugs mighl bo spurious, related ··;
to multiple loiing and siatistical variabilitji·.
Um ihc in.lin π.·.·>ιι!ι is still that overall there ·
is no inuo.iiod l i sk of ihicture associated·
with hoii/odia/opirios. Thi· risks
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